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abstract
PURPOSE Effective treatment options are limited for patients with advanced (metastatic or unresectable)
melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell therapy using
tumor-infiltrating lymphocytes has demonstrated efficacy in advanced melanoma. Lifileucel is an autologous,
centrally manufactured tumor-infiltrating lymphocyte product.
METHODS We conducted a phase II open-label, single-arm, multicenter study in patients with advanced
melanoma who had been previously treated with checkpoint inhibitor(s) and BRAF 6 MEK targeted agents.
Lifileucel was produced from harvested tumor specimens in central GoodManufacturing Practice facilities using
a streamlined 22-day process. Patients received a nonmyeloablative lymphodepletion regimen, a single infusion
of lifileucel, and up to six doses of high-dose interleukin-2. The primary end point was investigator-assessed
objective response rate (ORR) per RECIST, version 1.1.
RESULTS Sixty-six patients received a mean of 3.3 prior therapies (anti–programmed death 1 [PD-1] or
programmed death ligand 1 [PD-L1]: 100%; anticytotoxic T-lymphocyte-associated protein-4: 80%;
BRAF 6 MEK inhibitor: 23%). The ORR was 36% (95% CI, 25 to 49), with two complete responses and 22
partial responses. Disease control rate was 80% (95% CI, 69 to 89). Median duration of response was not
reached after 18.7-month median study follow-up (range, 0.2-34.1 months). In the primary refractory to anti–
PD-1 or PD-L1 therapy subset, the ORR and disease control rate were 41% (95% CI, 26 to 57) and 81% (95%
CI, 66 to 91), respectively. Safety profile was consistent with known adverse events associated with non-
myeloablative lymphodepletion and interleukin-2.
CONCLUSION Lifileucel demonstrated durable responses and addresses a major unmet need in patients with
metastatic melanoma with limited treatment options after approved therapy, including the primary refractory to
anti–PD-1 or PD-L1 therapy subset.
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INTRODUCTION
The treatment of advanced (unresectable or meta-
static) melanoma with immune checkpoint inhibitors
(ICI) and targeted oncogenic pathway inhibition with
BRAF and MEK inhibitors has improved patient
outcomes.1-7 Forty percent to 65% of patients with
advanced melanoma have primary resistance to
ICI.8-11 Of those with initial disease control, 30%-40%
develop acquired resistance.8,12 Approximately 15% to
20% of BRAF V600 mutation-positive patients fail to
respond to targeted therapy initially,13 and only 22%
remain progression-free at 3 years.14 Although primary
resistance is lower in patients treated with programmed
death 1 (PD-1) blocking antibody plus anticytotoxic
T-lymphocyte–associated protein 4 (CTLA-4) therapy,
36% of patients discontinue therapy because of
treatment-emergent adverse events (TEAEs), with 88%
developing immune-related adverse events (irAEs),
many of these being persistent.10 Patients progressing
after anti–PD-1 therapy, anti–PD-1 plus anti–CTLA-4
therapy, and targeted agents have limited options.15-17
Only 4%-10% of these patients have objective re-
sponses to chemotherapy, with a limited median overall
survival (OS) of 7 months.15,16,18,19 There are no treat-
ment options with approval based on data from patients
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one line of ICI therapy (for BRAF wild-type tumors), or two
lines of therapy (for BRAF V600 mutation-positive tumors).
In addition, patients recurring with advanced melanoma
after adjuvant anti–PD-1 therapy for high-risk disease rep-
resent an emerging unmet need.20-22
Adoptive cell therapy with tumor-infiltrating lymphocytes
(TIL) offers a potential therapeutic option for metastatic
melanoma, although it has not been studied extensively in
the ICI era.23-25 TIL are enriched with polyclonal T cells with
diverse antigen specificity.26 Extraction of a fragment of
tumor followed by ex vivo expansion removes TIL from the
hostile tumor microenvironment and reduces the immu-
nosuppressive effects of intratumoral regulatory T cells.
Expansion of TIL ex vivo rejuvenates the cells, yielding
billions of such cells to be infused back into the patient.
Melanoma is characterized by a high mutational burden27
and highly individualized neoantigens.28 A cellular therapy
product that can address the broad nature of neoantigens
and the unique array from each patient would lead to the
possibility of a tailored response. Lifileucel (LN-144) is an
autologous TIL therapy that uses tumor-tissue T cells ca-
pable of recognizing tumor antigens and being expanded
ex vivo while maintaining the heterogeneous repertoire of
T cells, using a centralized manufacturing process. We
report the safety and efficacy of lifileucel, a one-time cel-
lular therapy, in patients with advanced melanoma who




The study was approved by the institutional review board at
each site and was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guide-
lines of the International Conference on Harmonization. All
patients provided written informed consent. The study was
designed and sponsored by Iovance Biotherapeutics, Inc.
All authors discussed, analyzed, and interpreted the re-
sults, and vouch for the accuracy and completeness of the
data analyses and adherence to the Protocol (online only).
All authors contributed to this study and the writing of the
manuscript. Professional medical writing or editorial as-
sistance was paid for by the sponsor.
Patients and Study Design
The parent study (ClinicalTrials.gov identifier: NCT02360579)
consisted of multiple cohorts (Data Supplement, online
only). Cohort 2 data are reported here. Patients were
enrolled from April 2017 to January 2019 at 26 sites (see
the Data Supplement for investigator list).
Patients had unresectable or metastatic melanoma (stage
IIIC or IV) with confirmed radiologic progression. Patients
must have progressed following one or more prior systemic
therapies including a PD-1–blocking antibody and if BRAF
V600 mutation-positive, a BRAF 6 MEK inhibitor. Key
eligibility criteria are detailed in the Data Supplement.
Patients with a history of irAEs were eligible, as outlined in
the Data Supplement.
At least one resectable lesion (or aggregate of lesions)
measuring a minimum of 1.5 cm in diameter postresection
was required. Resected tumor was processed in a protocol-
specified manner and shipped to a Good Manufacturing
Practice facility in the provided tumor procurement kit. The
optimized manufacturing conditions involved a centralized
22-day process, resulting in a cryopreserved product (Data
Supplement). Lifileucel (LN-144) was shipped to the
clinical sites after meeting prespecified release criteria.
Patients received a nonmyeloablative lymphodepleting
(NMA-LD) regimen with cyclophosphamide (60 mg/kg)
once daily for 2 days followed by fludarabine (25 mg/m2)
once daily for 5 days. A single infusion of lifileucel (13 109
– 150 3 109 cells) was thawed and administered after
approximately 24 hours from the last dose of fludarabine. A
CONTEXT
Key Objective
This study evaluated the efficacy and safety of lifileucel, a one-time, autologous tumor-infiltrating lymphocyte (TIL) product,
in patients with metastatic melanoma who had progressed on standard immune checkpoint inhibitors (ICI) and targeted
therapies (if applicable), who otherwise have limited treatment options. Notably, chemotherapy post-ICI shows poor
response rates (4%-10%).
Knowledge Generated
Sixty-six patients received lifileucel infusion with . 1 3 109 TIL cells. Lifileucel was efficacious with an objective response
rate of 36%, and a median duration of response that is not reached at 18.7-month median study follow-up.
Relevance
Lifileucel represents a significant improvement in the treatment of advanced melanoma, particularly in the post-ICI patient
population, which is an expanding population. The study contributes to the advancement in TIL therapy through a
centrally standardized manufacturing approach for autologous TIL, allowing broader patient access.
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short course of bolus interleukin (IL)-2 (600,000 IU/kg) was
infused every 8-12 hours for up to six doses, starting within
3-24 hours of completing lifileucel infusion.
End Points and Assessments
The primary objective was to evaluate the efficacy of a
single infusion of lifileucel in patients with unresectable or
metastatic melanoma using investigator-assessed objective
response rate (ORR) by RECIST v1.1.29 Secondary end
points included duration of response (DOR), disease
control rate (DCR), OS, and safety. Efficacy assessments
started at week 6. Subsequent efficacy, adverse event (AE),
and serious AE (SAE) assessment schedules are outlined in
the Data Supplement.
Statistical Analysis
The analyses for efficacy and safety were conducted on the
full analysis set (FAS), defined as patients from cohort 2
who received lifileucel that met manufacturer’s specifica-
tions, including a cell dose 1 3 109 – 150 3 109. The
planned sample size was 60 based on estimation of ORR
using the maximum half-width of the two-sided 95% CI
of , 13.2% when ORR is expected to be 20%-50%. This
was considered meaningful, assuming that the historical
response rate of similar patients after chemotherapy is
10%.15,30 The FAS consisted of 66 patients because of
rapid enrollment.
The ORR was analyzed as a binomial proportion with two-
sided 95% CI estimated based on the Clopper-Pearson
TABLE 1. Patient Demographics and Baseline Characteristics
Characteristic Cohort 2 (N 5 66)




Melanoma stage at study entry
IIIC 9 (14)
IV 57 (86)
Prior therapies, No. (%)
Mean No. of prior therapies (SD) 3.3 (1.69)
Anti–PD-1 or PD-L1a 66 (100)
Anti–CTLA-4b 53 (80)
Anti–PD-1 plus CTLA-4 combination 34 (52)




Progressive disease for at least one prior
therapy, No. (%)
Anti–PD-1 or PD-L1d 65/66 (99)
Anti–CTLA-4 41/53 (77)
Primary refractory to prior anti–PD-1 or
anti–PD-L1, No. (%)
42 (64)
Patients with baseline liver lesions, No. (%) 23 (35)
Patients with baseline brain lesions, No. (%) 7 (11)
Patients with baseline liver and/or brain lesions,
No. (%)
28 (42)
Baseline ECOG score, No. (%)
0 37 (56)
1 29 (44)
BRAF status, No. (%)
Mutated V600 17 (26)
Wild type 45 (68)
Unknown 3 (5)
Other 1 (2)
Baseline LDH, No. (%)
# ULN 39 (59)
1-2 3 ULN 19 (29)
. 2 3 ULN 8 (12)
PD-L1 status
TPS $ 5% 24 (36)
TPS , 5% 23 (35)
Missing 19 (29)
Target lesion sum of diameter
$ 70 mm, No. (%) 40 (61)
Mean (SD), mm 106 (71)
(continued in next column)
TABLE 1. Patient Demographics and Baseline Characteristics
(continued)
Characteristic Cohort 2 (N 5 66)
No. of target and nontarget lesions (at baseline)
. 3, No. (%) 51 (77)
Mean (SD) 6 (2.7)
Median (range) 5 (2-14)
Median time from stop of anti–PD-1 or PD-L1 to
TIL infusion (range), months
4.8 (1.6-56.5)
Abbreviations: CTLA-4, cytotoxic T-lymphocyte–associated protein
4; ECOG, Eastern Cooperative Oncology Group; IL, interleukin; LDH,
lactate dehydrogenase; PD-1, programmed cell death protein 1; PD-
L1, programmed death-ligand 1; SD, standard deviation; TIL, tumor-
infiltrating lymphocytes; TPS, tumor proportion score; ULN, upper limit
of normal.
aIncludes pembrolizumab, nivolumab, durvalumab, and
atezolizumab.
bIncludes ipilimumab and tremelimumab.
cOne patient received only BRAF inhibitor. Two patients were
enrolled under an earlier protocol version that did not require BRAF
V600 mutation-positive patients to receive BRAF 6 MEK inhibitors.
Percentage is calculated based on number of patients who were BRAF
V600E- or V600K-mutated and received a BRAF inhibitor (dabrafenib
or vemurafenib) 6 a MEK inhibitor (trametinib or cobimetinib).
dOne patient discontinued anti–PD-1 therapy because of toxicity and
then progressed on interval therapy before enrollment.
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exact method. Time-to-event efficacy end points were
estimated using the Kaplan-Meier product limit method,
and two-sided corresponding 95% CIs were based on log-
log transformation. Safety data were reported descriptively.
All statistical analyses were conducted using the Statistical
Analysis System (SAS) version 9.4.
RESULTS
Patients and Treatment
Seventy-eight patients underwent tumor resection. Sixty-six
patients received lifileucel (LN-144) infusion with. 13 109
but , 150 3 109 TIL cells and comprised the FAS. Three
patients either did not receive TIL or received, 13 109 TIL
cells, whereas nine patients could not be treated because of
other causes (Data Supplement). Table 1 details the de-
mographics and baseline characteristics. Patients had
received a mean of 3.3 lines of prior therapies (range, 1-9
lines). All patients had received prior anti–PD-1 or anti–
programmed death ligand 1 (PD-L1) therapy, and 53
(80%) had received prior anti–CTLA-4 therapy. Fifty-two
percent of the patients had received concurrent CTLA-4
plus PD-1 blockade. Notably, 99% had progressed on prior
anti–PD-1 or PD-L1 therapy, and 77% had progressed on
prior anti–CTLA-4 therapy. Overall, 42 patients (64%) had a
best response of progressive disease to initial anti–PD-1 or
PD-L1 therapy (primary refractory subset). Of the 17 pa-
tients who were BRAF V600 mutation-positive, 88% had
received BRAF6MEK inhibitors. Forty patients (61%) had a
baseline target lesion sum of diameters (SOD)$ 70 mm, 51
(77%) patients had more than three target and nontarget
lesions at baseline, and 27 (41%) had baseline lactate
dehydrogenase levels higher than institutional upper limit of
normal. Overall, patients had a high tumor burden at




ORR, No. (%) (95% CI) 24 (36) (25 to 49)
DCR, No. (%) (95% CI) 53 (80) (69 to 89)






Median DOR, months (range) Not reached (2.2-26.91)
NOTE. 1, censored.
Abbreviations: CR, complete response; DCR, disease control rate;
DOR, duration of response; ORR, objective response rate; PD,
progressive disease; PR, partial response; SD, stable disease.
CRPRSDPD



























FIG 1. Change in tumor burden of target lesions, response by subgroup, and response assessment in individual patients. (A) Waterfall plot depicting BOR as
assessed by investigator and the best change from baseline in the SOD of the target lesions (per RECIST v1.1 criteria) in the FAS. A change of2100% from
baseline is presented for CR assessment that includes lymph node lesions that resolved to, 10mm. The horizontal dashed line indicates a 30% reduction in
the tumor burden in the target lesions. Twelve patients had an increase in the SOD of the target lesions, whereas 50 patients had a decrease in the SOD of the
target lesions. Thirty patients (two CR, 22 PR, and six SD) had. 30% reduction in the SOD of the target lesions. Three patients had no post-TIL assessments
because of early death. One patient had no post-TIL assessment because of start of new anticancer therapy before day 42. (continued on next page)
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baseline (mean SOD for the target lesions: 106 mm); 28
patients (42%) had liver and/or brain lesions at baseline.
The harvested tumor was collected from a variety of sites,
such as skin, lymph nodes, liver, lung, peritoneum, mus-
culoskeletal sites, breast, and other organs. The median
number of cyclophosphamide and fludarabine doses were
2 (range, 1-2) and 5 (range, 2-5), respectively. The mean
number of TIL cells infused was 27.3 3 109 (range,
1.2 3 109 to 99.5 3 109). The median number of IL-2
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FIG 1. (Continued). (B) Forest plot for ORR (FAS) by subgroup per investigator assessment using the RECIST v1.1
criteria. 95% CI is calculated using the Clopper-Pearson Exact test. (continued on next page).
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Efficacy
Sixty-six patients received a lifileucel infusion of $ 1 3 109
TIL cells. At the data cutoff of April 23, 2020 (median follow-
up of 18.7 months [range, 0.2-34.1 months]), the in-
vestigator-assessed ORR was 36% (95% CI, 25 to 49) and
the DCR was 80% (95% CI, 69 to 89) (Table 2), with 2
(3%) complete responses (CRs), 22 (33%) partial re-
sponses (PRs), and 29 (44%) patients showing stable
disease (SD). Sixty-two patients (94%) had a baseline and
at least one postbaseline radiologic assessment. Of the
four patients in the FAS who did not undergo postbaseline
assessment, three had died of disease, and one received
an additional line of systemic therapy; all were considered
as not evaluable for best overall response. Of the evaluable
patients, 50 (81%) had a reduction in tumor burden
(Fig 1A). Data Supplement details the percentage change
in target SOD from baseline over time in patients who
achieved a confirmed response. Response to lifileucel was
observed regardless of age, prior anti–CTLA-4 use, BRAF
mutation status, PD-L1 status as measured by tumor
proportion score, baseline Eastern Cooperative Oncology
Group performance status, tumor burden (assessed by
lactate dehydrogenase elevation above upper limit of
normal and target lesion SOD at baseline), presence of
liver and/or brain lesions at baseline, and timing of prior
PD-1 therapy (Fig 1B).
Median time from lifileucel infusion to best response was
1.4 months (range, 1.3-8.7 months). Time to response for
individual patients is illustrated in Figure 1C; 19 of 24
patients achieved response by the time of first planned
assessment (6 weeks after lifileucel infusion). Only 25% of
patients had progressed after achieving a response. The
median DOR has not been reached (95% CI, 11.8 months
to not reached) (Fig 2A) with a 1-year DOR of 69% (95% CI,
46 to 84). The median OS was 17.4 months (95% CI, 11.0
to not reached; Fig 2B). Of the patients who had SD and PR
or CR, 38% and 92% patients, respectively, had an OS$ 1
year. Progression-free survival for the FAS is shown in the
Data Supplement, and duration of SD in individual patients
is outlined in the Data Supplement.
An efficacy analysis was performed for the primary-
refractory subset (42 patients primary refractory to anti–
PD-1 or PD-L1 therapy). The ORR was 41% (95% CI, 26 to
57), with 2 CRs (5%) and 15 PRs (36%), and the DCR was
81% (95% CI, 66 to 91). Seventeen (41%) of these patients
had SD, and five (12%) had progressive disease; three
patients were nonevaluable. Median DOR was not reached
for this subpopulation.
Thirty-four (52%) patients received anti–PD-1 plus anti–
CTLA-4 combination therapy, either as frontline (n 5 15,
23%), or after failing frontline therapy (n 5 19, 29%). The
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FIG 1. (Continued). (C) Swimmer’s plot showing time to first response, duration of response, and time on efficacy assessment in confirmed responders by investigator
per RECIST v1.1 criteria. Among 24 responders, 12 (50%) showed ongoing response to lifileucel, six (25%) had progressed, two (8%) had died, three (13%) started a
newanticancer therapy, and one patient discontinued assessment because of relocation. aBOR is best overall response on prior anti-PD-1 immunotherapy. bFor patient
22, a CR was not confirmed; therefore, the BORwith lifileucel for this patient was PR. Causes of death: patient 22: possible pulmonary embolism; patient 41: failure to
thrive. BOR, best overall response; CR, complete response; CTLA-4, cytotoxic T-lymphocyte–associated protein 4; ECOG, Eastern Cooperative Oncology Group; FAS,
full analysis set; ORR, objective response rate; PD, progressive disease; PD-1, programmed death 1; PD-L1, programmed death-ligand 1; PR, partial response; SD,
stable disease; SOD, sum of diameters; TIL, tumor-infiltrating lymphocytes; TPS, tumor proportion score; U, unknown; ULN, upper limit of normal.
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ORRs for lifileucel in these two subsets were 33% (5/15)
and 32% (6/19), respectively. The ORRs for lifileucel in
patients with primary resistance (n 5 17) or acquired re-
sistance (n 5 11) to anti–PD-1 plus anti–CTLA-4 combi-
nation therapy were 35% (6/17) and 27% (3/11),
respectively. Details of these patients who responded to
lifileucel are outlined in the Data Supplement.
Exploratory analyses of product-specific characteristics,
including levels of phenotypic markers of T-cell lineage,
memory subset, youth, activation or exhaustion, or
trafficking (Data Supplement), did not demonstrate
association with response. Tumor burden reductions
were seen across the continuum of cell doses (Data
Supplement).
Safety
All patients experienced at least one TEAE, with the most
common ($ 30%) grade 3 or 4 TEAEs being thrombocyto-
penia (82%), anemia (56%), febrile neutropenia (55%),
neutropenia (39%), hypophosphatemia (35%), leukopenia
(35%), and lymphopenia (32%) (Table 3), consistent with the
toxicity profile of NMA-LD and IL-2. Fatal TEAEs occurred in
two patients—1 death was because of intra-abdominal tumor
Median DOR (95% CI): NR (11.8 to NR)
No. at risk:
Total:
0 3 6 9 12 15 18 21 24 27

















Median OS (95% CI): 17.4 months  (11.0 to NR)
No. at risk:
Total:
0 3 6 9 12 15 18 21 24 27 30 33 36
















FIG 2. (A) The Kaplan-Meier curve for DOR in confirmed responders who achieved a PR or better. The DOR is
measured from the time point at which the initial measurement criteria are met for a PR or CR, whichever occurred
first, until the first date that PD or death occurred. (B) The Kaplan-Meier curve for OS in the full analysis set. OS was
defined as the time (inmonths) from the start date of lifileucel infusion to death because of any cause. Patients who
were alive at the time of data cutoff had their event times censored on the last date of their known survival status.
The median OS was 17.4 months (95% CI, 11.0 to NR), with 1-year OS of 58% (95% CI, 45 to 69). CR, complete
response; DOR, duration of response; NR, not reached; OS, overall survival; PD, progressive disease; PR, partial
response.
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hemorrhage reported as possibly related to TIL, and one was
because of acute respiratory failure assessed as not related to
TIL by the investigator. The incidence of TEAEs, including
grade 3 or 4 TEAEs, decreased rapidly over time (Fig 3) with
no lifileucel-related SAEs reported after 6 months, and no
recurrence of irAEs related to prior ICI. Tumor harvest AEs
related to surgery are outlined in the Data Supplement.
DISCUSSION
Treatment options for patients with advanced melanoma
who progress after treatment with ICI and BRAF 6 MEK
inhibitors are limited. Cytotoxic chemotherapy has shown
poor response rates,15,16,18,19 with a limited median OS of
7 months.15 Many of the patients in our study had
exhausted all approved therapy (mean lines of prior ther-
apy, 3.3). The encouraging antitumor activity of lifileucel
observed in our study addresses a major unmet need in
patients with advanced melanoma after progression on ICI,
and targeted agents if indicated.
Lifileucel, a one-time cellular therapy, represents a significant
improvement in the treatment of advanced melanoma, par-
ticularly the current post-ICI patient population. First, lifileucel
demonstrated anORR of 36%,meeting the study primary end
point in a patient population that had failed frontline anti–PD-1
therapy, the current standard of care. This is noteworthy
because prior TIL therapy studies were conducted in the pre-
ICI era, or enrolled a very small population of patients who had
received prior anti–PD-1 therapy.23-25,31 A previous cohort 2
analysis has demonstrated a high concordance rate of 89.4%
between the Independent Review Committee–assessed and
investigator-assessed ORR.32 Second, at a median 18.7-
month follow-up, the median DOR has not been reached,
emphasizing the durability of lifileucel responses in a
heavily pretreated post-ICI patient population with a high
baseline tumor burden. Third, the efficacy of lifileucel was
equivalent agnostic of PD-L1 status, BRAF mutation
status, or prior anti–CTLA-4 therapy. Lifileucel was effi-
cacious in the subset of patients who were primarily re-
fractory to anti–PD-1/PD-L1 therapy, demonstrating an
ORR of 41% and a DCR of 81% in this subgroup. Fur-
thermore, lifileucel demonstrated similar ORR in patients
who received anti–PD-1 plus anti–CTLA-4 combination
as a frontline therapy (33%) or after failing frontline
therapy (32%).
TIL recognize multiple tumor-specific neoantigens,33 which
may be required for response in solid tumors with high
mutational burden. Removal from the hostile microenvi-
ronment and ex vivo expansion enable TIL to evade a broad
array of immunosuppressive mechanisms. Indeed, both
downregulation of PD-1 expression and restored func-
tionality were reported for ex vivo expanded TIL.34,35 By
TABLE 3. TEAEs Occurring in $ 20% of Patients
Preferred Term, No. (%)
Cohort 2
(N 5 66)
Any Grade Grade 3 or 4 Grade 5
No. of patients reporting at least one TEAE 66 (100) 64 (97) 2 (3)a
Thrombocytopenia 59 (89) 54 (82) 0
Chills 53 (80) 4 (6) 0
Anemia 45 (68) 37 (56) 0
Pyrexia 39 (59) 11 (17) 0
Neutropeniab 37 (56) 26 (39) 0
Febrile neutropenia 36 (55) 36 (55) 0
Hypophosphatemia 30 (46) 23 (35) 0
Leukopeniab 28 (42) 23 (35) 0
Fatigue 26 (39) 1 (2) 0
Hypotension 24 (36) 7 (11) 0
Lymphopeniab 23 (35) 21 (32) 0
Tachycardia 23 (35) 1 (2) 0
Alopecia 19 (29) 0 0
Increased AST 19 (29) 0 0
Decreased appetite 19 (29) 1 (2) 0
Diarrhea 19 (29) 1 (2) 0
Hypokalemia 17 (26) 2 (3) 0
Hypoxia 17 (26) 10 (15) 0
Peripheral edema 17 (26) 1 (2) 0
Rash 17 (26) 3 (5) 0
Hypocalcemia 16 (24) 3 (5) 0
Hypomagnesemia 16 (24) 0 0
Increased weight 16 (24) 1 (2) 0
Increased ALT 15 (23) 2 (3) 0
Nausea 15 (23) 0 0
Increased blood alkaline phosphatase 14 (21) 2 (3) 0
Dyspnea 14 (21) 3 (5) 0
Hypoalbuminemia 14 (21) 3 (5) 0
Maculopapular rash 14 (21) 6 (9) 0
Vomiting 14 (21) 0 0
Constipation 13 (20) 0 0
Pruritus 13 (20) 0 0
Abbreviations: AE, adverse event; TEAE, treatment-emergent adverse event; TIL,
tumor-infiltrating lymphocytes.
aOne death was because of intra-abdominal hemorrhage reported as possibly
related to TIL, and one was because of acute respiratory failure assessed as not
related to TIL by the investigator.
bAll patients had grade 4 laboratory abnormality per the Common Terminology
Criteria for Adverse Events v4.03 for leukopenia, neutropenia, and lymphopenia
during the treatment-emergent period. Only clinically significant laboratory
abnormalities per investigators were reported as AEs.
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contrast, ICI target only a limited number of pathways
in situ. Additionally, in vitro culture results in large-scale
expansion of TIL, potentially increasing the number of
tumor-specific T cells available for tumor targeting after
adoptive transfer. The T cells comprising the TIL product
are recovered directly from the tumor tissue, a site enriched
for T-cell clones that are able to recognize patient-specific
tumor antigens.36,37 As a result, a polyclonal product is
obtained that has the potential to target multiple relevant
antigens, addressing (1) the ability to identify the unique
spectrum of patient-specific tumor antigens38; (2) the
heterogeneous nature of solid tumors39; and (3) immune
escape through antigen loss.40 Finally, substantial fractions
of TIL-derived T cells were shown to persist for at least
6 weeks,41 consistent with the memory phenotype of the
majority of the T cells comprising the product.35 These
varied mechanisms and TIL properties likely contribute to
the antitumor efficacy of lifileucel.
The tumors were harvested with minimal surgical morbidity,
although 58% were extranodal or nonskin/subcutaneous
lesions. A small subset of enrolled patients (12%) could
not be treated because of progression, death, or other causes.
TEAEs occurred during or immediately after NMA-LD or
IL-2 administration and were generally transient, with no
new lifileucel-associated SAEs reported after 6 months.
Although patients were hospitalized for NMA-LD and IL-2
administration, lifileucel is a one-time cellular therapy with
durable responses, as demonstrated by an ongoing re-
sponse in 50% of responders at a median follow-up of
18.7 months. In addition, the safety profile indicates that
lifileucel is a viable option for patients who are not eligible
for ICI because of prior significant irAEs, as it is not as-
sociated with recrudescence of irAEs.
Single-center studies conducted at NCI23,31 have been
important in laying the groundwork for TIL therapy in pa-
tients with advanced melanoma but were limited to a few
centers with dedicated on-site cell therapy facilities. Al-
though lifileucel centralized manufacturing required ship-
ping of the tumor samples, TIL could be manufactured in
96% of patients. The present multicenter study constitutes
a significant advance by successfully demonstrating the
feasibility of a centrally standardized manufacturing ap-
proach for TIL therapy, which allows for broadened patient
access, whereas cryopreservation of lifileucel provides
flexibility in treatment scheduling in the real-world clinical
setting.
In summary, lifileucel, a first-in-class centrally manufac-
tured autologous TIL cell therapy, was efficacious and
demonstrated durable responses in heavily pretreated
patients and represents a potential new standard of care for
patients with advanced melanoma following failure of ICI
and targeted therapy. Patients with advanced melanoma
who have failed anti–PD-1 therapy (and BRAF 6 MEK
inhibitors if BRAF V600 mutation-positive), irrespective of
baseline tumor characteristics, should be considered for
the one-time lifileucel therapy as second-line therapy
(third-line if BRAF V600 mutation positive) if they have
performance status and organ function adequate for ad-
ministration of lymphodepleting chemotherapy and a














D0 D14 M1 M2 M3 M4 M5 M6






FIG 3. AEs over time. The distribution of onset of AEs starting from lifileucel infusion until 6 months postinfusion is
shown. A TEAEwas defined as any AE with onset after start of lifileucel through day 30 postinfusion. All occurrences of
AEs were counted if a patient experienced a new onset of the same AE at different timepoints. If multiple records were
reported on the electronic case report form because of toxicity grade decrease of the same AE that had not resolved,
then the event was counted once with the highest grade reported. Overall, 24 AEs were reported post month 6 until
data cutoff date, which are not shown in the histogram. No SAEs related to lifileucel were reported post month 6. AE,
adverse event; D, day; M, month; SAE, serious adverse event; TEAE, treatment-emergent adverse event; TIL, tumor-
infiltrating lymphocytes.
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Administration has granted lifileucel a Regenerative Med-
icine Advanced Therapy designation, Orphan Drug des-
ignation, and a Fast Track designation for advanced
melanoma. Based on these encouraging results, an ad-
ditional cohort has been fully enrolled, using Independent
Review Committee–assessed ORR for registration pur-
poses. Given the favorable risk-benefit profile of lifileucel,
its role earlier in the disease course and in combination with
ICI is being investigated in melanoma, as well as additional
studies in other metastatic solid malignancies.
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